Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Benjamin Heyman, MD, Michael Y. Choi, MD, Emanuela M. Ghia, PhD, George F. Widhopf II, PhD, Minya Pu, PhD, Emily Pittman, PhD, Karen Messer, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-134711

Published: 2020

Journal Articles

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Emanuela M. Ghia, PhD, Laura Z. Rassenti, PhD, Michael Y. Choi, MD, Elvin Chu, George F. Widhopf II, PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 476.

https://doi.org/10.1182/blood-2019-131426

Published: 2019

Journal Articles

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 4274.

https://doi.org/10.1182/blood-2019-131600

Published: 2019

Journal Articles

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Han Zhang, PhD, Suping Zhang, PhD, Emanuela M. Ghia, PhD, Michael Y. Choi, MD, Jieyu Zhang, MS, Liguang Chen, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 2652.

https://doi.org/10.1182/blood-2018-99-119606

Published: 2018

Journal Articles

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Thomas Kipps, MD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 4404.

https://doi.org/10.1182/blood-2018-99-117175

Published: 2018

Journal Articles

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Yun Chen, PhD, Michael Y. Choi, MD, Liguang Chen, PhD, Jian Yu, PhD, Ling Zhang, Emanuela M. Ghia, PhD, Elsa Sanchez-Lopez, PhD, George F. Widhopf II, PhD, Karen Messer, PhD, Laura Z. Rassenti, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2018) 132 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2018-99-111996

Published: 2018

Journal Articles

ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia

Emanuela M. Ghia, PhD, Michael Y. Choi, MD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 1853.

https://doi.org/10.1182/blood-2018-99-119711

Published: 2018

Journal Articles

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Yousaf A. Mian, PhD, George F. Widhopf II, PhD, Thanh-Trang Vo, PhD, Katti Jessen, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD

Blood (2018) 132 (Supplement 1): 1862.

https://doi.org/10.1182/blood-2018-99-119447

Published: 2018

Journal Articles

Wnt5a Induces ROR1 to Complex with DOCK2 and Promote Proliferation of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, PhD, Jian Yu, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Liguang Chen, PhD, Zhouxin Shen, PhD, Steven P. Briggs, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 388.

https://doi.org/10.1182/blood.V130.Suppl_1.388.388

Published: 2017

Journal Articles

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

Michael Choi, MD, George F. Widhopf II, PhD, Jian Yu, PhD, Liguang Chen, PhD, Md. Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, Emily Pittman, PhD, Karen Messer, PhD, Charlene Gutierrez, BS, Reilly Lilianna Kidwell, BSc, Charles E. Prussak, PharmD, PhD, Januario E Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 829.

https://doi.org/10.1182/blood.V130.Suppl_1.829.829

Published: 2017

Journal Articles

Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, PhD, Jian Yu, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 389.

https://doi.org/10.1182/blood.V130.Suppl_1.389.389

Published: 2017

Journal Articles

Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway

Jian Yu, PhD, Yun Chen, PhD, Liguang Chen, PhD, Ling Zhang, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 4019.

https://doi.org/10.1182/blood.V130.Suppl_1.4019.4019

Published: 2017

Journal Articles

Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, PhD, Jian Yu, PhD, Liguang Chen, PhD, Bing Cui, PhD, Zhouxin Shen, PhD, George F. Widhopf, II, PhD, Laura Z. Rassenti, PhD, Steven P. Briggs, PhD, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 301.

https://doi.org/10.1182/blood.V128.22.301.301

Published: 2016

Journal Articles

Cirmtuzumab Targets ROR1 to Inhibit Ibrutinib-Resistant, Wnt5a-Induced Rac1 Activation in Chronic Lymphocytic Leukemia

Jian Yu, PhD, Liguang Chen, PhD, Bing Cui, PhD, Christina Wu, PhD, Michael Y. Choi, MD, Yun Chen, PhD, Ling Zhang, Laura Z. Rassenti, PhD, George F. Widhopf, II, PhD, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 2034.

https://doi.org/10.1182/blood.V128.22.2034.2034

Published: 2016

Journal Articles

Wnt5a Induces Association of ROR1 with 14-3-3ζ to Enhance Chemotaxis and Proliferation in Chronic Lymphocytic Leukemia

Jian Yu, PhD, Liguang Chen, PhD, Yun Chen, PhD, Ling Zhang, Laura Z. Rassenti, PhD, George F. Widhopf, II, PhD, Zhouxin Shen, PhD, Steven P. Briggs, PhD, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 349.

https://doi.org/10.1182/blood.V128.22.349.349

Published: 2016

Journal Articles

Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Jian Yu, PhD, Reilly L Kidwell, BS, BA, CCRC, Laura Z. Rassenti, PhD, Charlene Gutierrez, Susette Gorak, Tiffany Juarez, PhD, Emily Pittman, PhD, Hongying Li, PhD, Karen Messer, PhD, Charles Prussak, PhD, Januario E. Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 3224.

https://doi.org/10.1182/blood.V128.22.3224.3224

Published: 2016

Journal Articles

Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Januario Castro, MD, Hongying Li, PhD, Reilly L Kidwell, BS, BA, CCRC, Sam C Zhang, B.A., Tiffany Juarez, PhD, Susette Gorak, Laura Z. Rassenti, PhD, Karen Messer, PhD, Charles Prussak, PhD, Catriona HM Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2015) 126 (23): 1736.

https://doi.org/10.1182/blood.V126.23.1736.1736

Published: 2015

Journal Articles

Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961)

Jian Yu, PhD, Liguang Chen, MD PhD, George F. Widhopf, II, PhD, Suping Zhang, PhD, Bing Cui, PhD, Rongrong Wu, PhD, Ling Zhang, PhD, Thomas J. Kipps, MD, PhD

Blood (2015) 126 (23): 1741.

https://doi.org/10.1182/blood.V126.23.1741.1741

Published: 2015

Journal Articles

Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1

George F. Widhopf, II, PhD, Bing Cui, Ph.D., Christina C.N. Wu, PhD, Jian Yu, PhD, Fitzgerald Lao, Rommel Tawatao, Rongrong Wu, Esther Avery, B.S., Anil Sadarangani, PhD, Charles Prussak, PhD, Catriona HM Jamieson, MD, PhD, Dennis A. Carson, M.D., Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 2873.

https://doi.org/10.1182/blood.V122.21.2873.2873

Published: 2013

Journal Articles

Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors

Bing Cui, Ph.D, George F. Widhopf, II, PhD, Charles E. Prussak, Ph.D., Christina C.N. Wu, PhD, Anil Sadarangani, PhD, Suping Zhang, PhD, Fitzgerald Lao, Catriona HM Jamieson, MD, PhD, Dennis A. Carson, M.D, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 1637.

https://doi.org/10.1182/blood.V122.21.1637.1637

Published: 2013

NARROW

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Wnt5a Induces ROR1 to Complex with DOCK2 and Promote Proliferation of Chronic Lymphocytic Leukemia Cells

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells

Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway

Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia

Cirmtuzumab Targets ROR1 to Inhibit Ibrutinib-Resistant, Wnt5a-Induced Rac1 Activation in Chronic Lymphocytic Leukemia

Wnt5a Induces Association of ROR1 with 14-3-3ζ to Enhance Chemotaxis and Proliferation in Chronic Lymphocytic Leukemia

Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia

Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts

Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961)

Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1

Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only